AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$UTHR

ROTHBLATT MARTINE A sold $4.8M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $501.59 ($499.77–$504.57, $4.77M total) across 6 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 16, 2026, 8:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

While the transaction is newly disclosed, its modest size and pre‑arranged nature limit actionable insight.

02

Market read

The filing provides a fresh data point on insider activity but is unlikely to move the stock significantly.

03

What to watch

The 10b5‑1 plan indicates the sale was pre‑scheduled, reducing the informational value of the transaction.

Relevance 5/10Novelty 6/10Timing: post‑market filing on Sep 15, reported Sep 16

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals about company outlook.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO Martine Rothblatt sold $4.8M of United Therapeutics shares via a 10b5‑1 plan on Sep 15, reducing her stake to 324,443 shares.

Expected impact

Potential short‑term dip of 0.5‑1% if market reacts to the sale.

Evidence & confidence

A $4.8M sale by the CEO is material enough to be noted, yet it represents a tiny fraction of total shares outstanding, limiting price impact.

Market effects

Sector

Minimal effect on the biotech/biopharma sector; insider sales are common and not sector‑wide drivers.

Regional

Limited to U.S. markets where United Therapeutics trades.

Global

Negligible global impact.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event under a pre‑arranged plan, not a bearish signal.

Key entities

  • Company
    United Therapeutics Corp

    Biopharma company developing organ transplantation and pulmonary therapies.

  • Executive
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

SEP 10
$UTHRMed

Is United Therapeutics (UTHR) A Bargain Following Its Tyvaso FDA Acceptance?

United Therapeutics (UTHR) is under scrutiny after the FDA accepted its supplemental New Drug Application for Tyvaso in idiopathic pulmonary fibrosis. The company's stock has seen short-term declines, but long-term returns remain strong. Analysts suggest UTHR may be undervalued, with a fair value estimate of $665.23, citing its drug pipeline and innovation. However, risks include potential trial disappointments and competition.

simplywall.st2 min
SEP 9
$UTHRMed

United Therapeutics at Cantor healthcare conference: fibrosis push widens

United Therapeutics (UTHR) announced a strategic shift toward pulmonary fibrosis at the Cantor Fitzgerald Global Healthcare Conference, aiming for a 10-fold market expansion. The company presented strong clinical data for nebulized Tyvaso, with FDA review expected by April 2027. Management also announced a $500M stock repurchase and plans for 14 product launches through 2029, including new Tyvaso formulations and ralinepag products. The company projects a significant revenue opportunity in the p

investing.com3 min
SEP 9
$UTHRMedAI 8/10

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

United Therapeutics (UTHR) stock rose 4.3% post-earnings, trading at $214.36. Myriad Genetics (MYGN) reported $190.7M revenue, down 10.5% YoY, missing estimates, and guidance fell short, causing a 40.9% stock drop to $3.18. Gilead Sciences (GILD) reported $7.8B revenue, up 10.2% YoY, beating estimates, with stock up 8.1% to $146.16. Novavax (NVAX) reported $56.7M revenue, down 76.3% YoY, but beat estimates, with stock up 32.2% to $10.18.

finance.yahoo.com3 min